군발두통 환자 수 분석과 예측(2026-2035년)

Cluster headache is characterized by recurrent attacks of severe unilateral headache accompanied by cranial autonomic symptoms such as tearing, nasal congestion, eyelid edema, and facial sweating. The condition is classified into episodic and chronic forms, both of which significantly impair quality of life, productivity, and mental health. Patient population analysis provides valuable insights into disease prevalence, incidence, demographic distribution, diagnosed and undiagnosed populations, disease severity, treatment patterns, and future epidemiological trends that support pharmaceutical development, healthcare planning, and commercial decision-making.

Market Drivers

Increasing Disease Awareness

Growing awareness among neurologists, primary care physicians, and patient advocacy organizations is improving recognition of cluster headache and reducing diagnostic delays. Wider adoption of standardized diagnostic criteria is contributing to increased identification of patients requiring specialized treatment.

Improved Diagnostic Accuracy

Advances in headache classification guidelines and greater differentiation between cluster headache, migraine, and other primary headache disorders are increasing diagnosis rates across healthcare systems.

Expansion of Specialist Headache Centers

The establishment of specialized headache clinics and neurological care centers is improving patient access to expert diagnosis, comprehensive disease management, and preventive treatment.

Growing Recognition of Disease Burden

Increasing understanding of the significant physical, psychological, occupational, and socioeconomic burden associated with cluster headache is encouraging earlier diagnosis, long-term follow-up, and improved epidemiological reporting.

Market Restraints

High Rate of Misdiagnosis

Cluster headache is frequently misdiagnosed as migraine, sinus headache, or trigeminal neuralgia, delaying appropriate treatment and resulting in underestimation of the true patient population.

Limited Epidemiological Data

Because cluster headache is a rare disorder, large population-based epidemiological studies remain limited in many countries, creating variability in prevalence estimates.

Limited Access to Specialist Care

Many patients continue to experience delayed diagnosis because of shortages of neurologists, headache specialists, and dedicated headache clinics, particularly in low- and middle-income countries.

Patient Population Insights

The global cluster headache patient population can be segmented by disease subtype, disease severity, age group, gender, diagnosis status, treatment status, and geography.

By disease subtype, the patient population includes episodic cluster headache and chronic cluster headache. Episodic disease accounts for approximately 80% to 90% of diagnosed cases, while chronic cluster headache represents a smaller but more clinically challenging patient population.

By disease severity, patients are categorized into mild, moderate, and severe disease, with severe and chronic cases requiring long-term preventive treatment and specialist neurological care.

By age group, the analysis includes pediatric, adolescent, adult, and geriatric populations. Most patients develop symptoms between 20 and 40 years of age, although pediatric onset is increasingly recognized as diagnosis improves.

By gender, cluster headache affects both men and women. Although men remain more frequently affected, recent studies indicate that the gender gap has narrowed substantially as diagnosis in women has improved.

By diagnosis status, the analysis evaluates diagnosed and undiagnosed patient populations, highlighting continued opportunities to improve disease awareness and diagnostic accuracy.

By treatment status, patients are classified into treated and untreated populations, reflecting differences in healthcare access, specialist referral, and availability of preventive therapies.

Epidemiology Trends

The global cluster headache patient population continues to evolve as diagnosis improves.

Key trends include:

• Increasing diagnosis through improved physician awareness.
• Growing recognition of chronic cluster headache.
• Better differentiation from migraine and other headache disorders.
• Expansion of specialized headache centers.
• Improved epidemiological surveillance and patient registries.
• Greater use of digital headache diaries and remote patient monitoring.
• Rising demand for preventive therapies and multidisciplinary disease management.

Regional Insights

North America represents one of the largest diagnosed cluster headache patient populations because of advanced neurological care, specialized headache clinics, established diagnostic guidelines, and greater disease awareness.

Europe maintains a significant patient population supported by comprehensive healthcare systems, active headache research programs, and expanding access to specialist neurology services.

Asia-Pacific is expected to experience the fastest growth in diagnosed patient numbers owing to improving healthcare infrastructure, increasing awareness of headache disorders, expanding neurological services, and greater participation in epidemiological research.

Latin America and the Middle East & Africa are gradually improving diagnosis and patient identification through healthcare modernization, physician education, and increasing access to neurological care.

Competitive Landscape

Cluster headache patient population analysis supports pharmaceutical companies, biotechnology firms, healthcare providers, academic researchers, and policymakers in evaluating disease burden and future commercial opportunities.

Organizations increasingly utilize epidemiological data for clinical trial planning, patient recruitment, market forecasting, healthcare resource allocation, reimbursement planning, and commercialization strategies. The growing use of real-world evidence, digital headache registries, and electronic health records continues to strengthen patient population assessment.

Future Outlook

The global cluster headache patient population is expected to continue expanding through 2035 as disease awareness improves, diagnostic delays decrease, and access to specialist headache care increases. Advances in digital health, artificial intelligence-assisted diagnosis, wearable monitoring technologies, and real-world evidence are expected to enhance epidemiological surveillance and facilitate earlier diagnosis.

Continued investment in headache research and patient registries will improve understanding of disease burden while supporting development of targeted therapies and optimized healthcare planning.

Conclusion

The global Cluster Headache Patient Population Analysis highlights the growing recognition of cluster headache as a severe neurological disorder with significant clinical and socioeconomic burden. Increasing physician awareness, improved diagnosis, expanding access to specialist care, and better epidemiological surveillance are expected to drive continued growth in the diagnosed patient population. Although challenges related to misdiagnosis, underreporting, and limited access to specialist services remain, advances in neurological care and digital health technologies are expected to improve patient identification and long-term disease management.

Key Benefits of this Report

• Comprehensive analysis of the global cluster headache patient population and epidemiological trends.
• Detailed evaluation of prevalence, incidence, diagnosed, treated, and untreated patient populations.
• Assessment of demographic distribution by age, gender, disease subtype, severity, and geography.
• Insights into disease burden, unmet clinical needs, and future patient growth opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Epidemiology forecasting, patient population estimation, clinical trial planning, market opportunity assessment, healthcare resource planning, investment analysis, commercialization strategy, reimbursement planning, and strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global cluster headache patient population by disease subtype, disease severity, age group, gender, diagnosis status, treatment status, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, treated and untreated populations, and epidemiological trends
• Assessment of demographic characteristics, disease burden, healthcare utilization, diagnostic patterns, and unmet clinical needs
• Analysis of regional epidemiology, patient growth trends, healthcare infrastructure, disease awareness initiatives, and future opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Epidemiology Insights
• 1.3 Treatment Landscape Overview
• 1.4 Major Market Trends
• 1.5 Key Growth Opportunities
• 1.6 Competitive Overview
• 1.7 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Disease Overview
  • 2.1.1 Definition of Cluster Headache
  • 2.1.2 Disease Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Etiology and Risk Factors
  • 2.1.5 Signs and Symptoms
  • 2.1.6 Disease Burden
• 2.2 Diagnosis and Clinical Assessment
  • 2.2.1 Diagnostic Criteria
  • 2.2.2 Differential Diagnosis
  • 2.2.3 Imaging and Laboratory Assessment
  • 2.2.4 Disease Severity Assessment
• 2.3 Epidemiology Analysis
  • 2.3.1 Historical and Current Patient Population
  • 2.3.2 Incident Cases
  • 2.3.3 Diagnosed Patient Population
  • 2.3.4 Gender-wise Patient Population
  • 2.3.5 Age-wise Patient Population
  • 2.3.6 Episodic Cluster Headache Patient Population
  • 2.3.7 Chronic Cluster Headache Patient Population
  • 2.3.8 Treated Patient Population
  • 2.3.9 Epidemiology Forecast

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
• 3.3 Market Restraints
• 3.4 Market Opportunities
• 3.5 Market Challenges
• 3.6 Unmet Needs
• 3.7 Impact of Emerging Therapies
• 3.8 Porter's Five Forces Analysis
• 3.9 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis
• 4.4 Healthcare Spending Trends
• 4.5 Patient Access Programs
• 4.6 Insurance Coverage Trends
• 4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Pipeline Overview
• 5.3 Pipeline Analysis by Development Stage
  • 5.3.1 Phase I Pipeline
  • 5.3.2 Phase II Pipeline
  • 5.3.3 Phase III Pipeline
  • 5.3.4 Preclinical Pipeline
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Calcitonin Gene-Related Peptide (CGRP) Pathway
  • 5.4.2 Neuromodulation Technologies
  • 5.4.3 Serotonin Receptor Modulators
  • 5.4.4 Other Emerging Mechanisms
• 5.5 Pipeline Analysis by Modality
  • 5.5.1 Small Molecules
  • 5.5.2 Monoclonal Antibodies
  • 5.5.3 Medical Devices
  • 5.5.4 Digital and Neuromodulation Technologies
• 5.6 Clinical Trial Landscape
• 5.7 Emerging Technologies and Innovations

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Treatment Options
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
  • 6.2.3 Intranasal Therapies
  • 6.2.4 Other Acute Treatments
• 6.3 Preventive Treatment Options
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 Corticosteroids
  • 6.3.3 CGRP Monoclonal Antibodies
  • 6.3.4 Neuromodulation Therapies
  • 6.3.5 Other Preventive Therapies
• 6.4 Treatment Algorithm
• 6.5 Clinical Practice Guidelines
• 6.6 Unmet Needs in Treatment

7. Global Cluster Headache Patient Population Analysis Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis
• 7.3 Forecast Market Size Analysis
• 7.4 Market Attractiveness Analysis
• 7.5 Incremental Growth Opportunity
• 7.6 Absolute Dollar Opportunity

8. Global Cluster Headache Patient Population Analysis Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatment
• 8.2 By Disease Type
  • 8.2.1 Episodic Cluster Headache
  • 8.2.2 Chronic Cluster Headache
• 8.3 By Gender
  • 8.3.1 Male
  • 8.3.2 Female
• 8.4 By Age Group
  • 8.4.1 Pediatric
  • 8.4.2 Adult
  • 8.4.3 Geriatric
• 8.5 By Route of Administration
  • 8.5.1 Oral
  • 8.5.2 Injectable
  • 8.5.3 Intranasal
• 8.6 By Care Setting
  • 8.6.1 Hospitals
  • 8.6.2 Specialty Clinics
  • 8.6.3 Homecare Settings
  • 8.6.4 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Epidemiology Overview
  • 9.1.3 Demand Drivers
  • 9.1.4 Regulatory Overview
  • 9.1.5 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Epidemiology Overview
  • 9.2.3 Demand Drivers
  • 9.2.4 Regulatory Overview
  • 9.2.5 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Epidemiology Overview
  • 9.3.3 Demand Drivers
  • 9.3.4 Regulatory Overview
  • 9.3.5 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Epidemiology Overview
  • 9.4.3 Demand Drivers
  • 9.4.4 Regulatory Overview
  • 9.4.5 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Epidemiology Overview
  • 9.5.3 Demand Drivers
  • 9.5.4 Regulatory Overview
  • 9.5.5 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Scenario
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 Europe Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Drug Approval Pathways
• 11.8 Medical Device Approval Pathways
• 11.9 Pharmacovigilance Requirements
• 11.10 Health Technology Assessment Landscape

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness
• 12.5 Strategic Developments
  • 12.5.1 Collaborations and Partnerships
  • 12.5.2 Mergers and Acquisitions
  • 12.5.3 Licensing Agreements
  • 12.5.4 Product Launches
  • 12.5.5 Clinical Trial Developments

13. Company Profiles

• 13.1 GlaxoSmithKline plc
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products and Generic Names
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Portfolio
  • 13.1.5 Recent Developments
• 13.2 Medtronic
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products and Devices
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Portfolio
  • 13.2.5 Recent Developments
• 13.3 Eli Lilly and Company
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products and Generic Names
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Recent Developments
• 13.4 electroCore, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products and Devices
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Recent Developments
• 13.5 Pfizer Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products and Generic Names
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Recent Developments
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Approved Products and Generic Names
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Portfolio
  • 13.6.5 Recent Developments
• 13.7 Viatris Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products and Generic Names
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Portfolio
  • 13.7.5 Recent Developments
• 13.8 Autonomic Technologies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products and Devices
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Portfolio
  • 13.8.5 Recent Developments
• 13.9 Zosano Pharma Corp.
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products and Generic Names
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Portfolio
  • 13.9.5 Recent Developments
• 13.10 Bausch Health Companies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Approved Products and Generic Names
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Portfolio
  • 13.10.5 Recent Developments

14. Future Outlook

• 14.1 Future Epidemiology Trends
• 14.2 Emerging Treatment Trends
• 14.3 Innovation Outlook
• 14.4 Market Growth Projections
• 14.5 Strategic Recommendations
• 14.6 Scenario Analysis

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Primary Research
• 15.4 Secondary Research
• 15.5 Epidemiology Modeling Approach
• 15.6 Market Estimation Methodology
• 15.7 Forecasting Methodology
• 15.8 Data Triangulation
• 15.9 Assumptions and Limitations
• 15.10 Abbreviations and Definitions